Антагонист рецепторов ангиотензина II кандесартан в арсенале терапевта
Антагонист рецепторов ангиотензина II кандесартан в арсенале терапевта
Кириченко А.А. Антагонист рецепторов ангиотензина II кандесартан в арсенале терапевта. Consilium Medicum. 2016; 18 (10): 76–81. DOI: 10.26442/2075-1753_2016.10.76-81
________________________________________________
Kirichenko A.A. Angiotensin II receptor antagonist – candesartan in the arsenal of therapist. Consilium Medicum. 2016; 18 (10): 76–81. DOI: 10.26442/2075-1753_2016.10.76-81
Антагонист рецепторов ангиотензина II кандесартан в арсенале терапевта
Кириченко А.А. Антагонист рецепторов ангиотензина II кандесартан в арсенале терапевта. Consilium Medicum. 2016; 18 (10): 76–81. DOI: 10.26442/2075-1753_2016.10.76-81
________________________________________________
Kirichenko A.A. Angiotensin II receptor antagonist – candesartan in the arsenal of therapist. Consilium Medicum. 2016; 18 (10): 76–81. DOI: 10.26442/2075-1753_2016.10.76-81
Приведено сопоставление фармакологических свойств, клинической эффективности блокаторов рецепторов ангиотензина II у пациентов с артериальной гипертензией, хронической сердечной недостаточностью (ХСН) и хронической болезнью почек. Высокое сродство, прочность связывания кандесартана с рецепторами ангиотензина 1-го типа, его медленная диссоциация из связи с ними и повторное связывание обеспечивают выраженное и длительное антигипертензивное и органопротективное действие. Терапевтическая эффективность кандесартана эквивалентна другим основным классам антигипертензивных препаратов. Применение кандесартана высокоэффективно при ХСН с систолической дисфункцией левого желудочка. В группе же больных с сохраненной функцией левого желудочка его эффективность остается менее доказанной. Отмечено снижение риска развития фибрилляции предсердий на фоне лечения кандесартаном артериальной гипертензии и у пациентов с ХСН.
The article deals with the comparison of pharmacological characteristics and the clinical efficacy of angiotensin II receptor blockers in patients with arterial hypertension, chronic heart failure (CHF) and chronic kidney disease. High binding affinity to the angiotensin type 1 receptors, slow dissociation and repeated fixation of candesartan provide the expressed and prolonged duration of the antihypertensive and organoprotective actions. Therapeutic efficacy of candesartan is equivalent to that of other major classes of antihypertensive agents. The application of candesartan is highly effective in CHF associated with left ventricular systolic dysfunction. In the group of patients with preserved left ventricular function, candesartan efficacy is statistically significant. We show the decrease of risk of the developing atrial fibrillation in the course of candesartan treatment in hypertension patients with CHF.
1. Андрущишина Т.Б., Морозова Т.Е. Антагонисты рецепторов ангиотензина II при лечении кардиоваскулярных заболеваний. Consilium Medicum. 2009; 11 (5): 96–101. / Andrushchishina T.B., Morozova T.E. Antagonisty retseptorov angiotenzina II pri lechenii kardiovaskuliarnykh zabolevanii. Consilium Medicum. 2009; 11 (5): 96–101. [in Russian]
2. Jonston CI. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. Am J Hypertens 1992; 10: S13–S26.
3. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Рекомендации по диагностике и лечению артериальной гипертензии. Кардиологический вестн. 2015; 1: 3. / Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Rekomendatsii po diagnostike i lecheniiu arterial'noi gipertenzii. Kardiologicheskii vestn. 2015; 1: 3. [in Russian]
4. Linger Т. Differences among angiotensin II type 1 receptor blockers: characterization of 19. candesartan cilexetil. Blood Pressure 2000; 9 (1): 14–8.
5. Евдокимова А.Г., Ложкина М.В., Коваленко Е.В., Евдокимов В.В. Клиническая эффективность ирбесартана у пациентов с сердечно-сосудистыми заболеваниями. Сердце. 2012; 11 (6): 364–8. / Evdokimova A.G., Lozhkina M.V., Kovalenko E.V., Evdokimov V.V. Klinicheskaia effektivnost' irbesartana u patsientov s serdechno-sosudistymi zabolevaniiami. Serdtse. 2012; 11 (6): 364–8. [in Russian]
6. Jonston CI. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. Am J Hypertens 1992; 10: S13–S26.
7. Гиляревский С.Р. Современные возможности блокады ренин-ангиотензиновой системы: остаются ли ингибиторы ангиотензинпревращающего фермента препаратами первого ряда? Consilium Medicum. 2010; 12 (5): 18–23. / Giliarevskii S.R. Sovremennye vozmozhnosti blokady renin-angiotenzinovoi sistemy: ostaiutsia li ingibitory angiotenzinprevrashchaiushchego fermenta preparatami pervogo riada? Consilium Medicum. 2010; 12 (5): 18–23. [in Russian]
8. Остроумова О.Д., Хорьков С.А., Копченов И.И. Возможности антагонистов рецепторов к ангиотензину II в органопротекции у больных с артериальной гипертонией: значение для клинической практики. Consilium Medicum. 2009; 11. / Ostroumova O.D., Khor'kov S.A., Kopchenov I.I. Vozmozhnosti antagonistov retseptorov k angiotenzinu II v organoprotektsii u bol'nykh s arterial'noi gipertoniei: znachenie dlia klinicheskoi praktiki. Consilium Medicum. 2009; 11. [in Russian]
9. Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Доказательная история кандесартана: прошлое, будущее и настоящее. Сердечная недостаточность. 2015; 16 (5): 303–10. / Giliarevskii S.R., Golshmid M.V., Kuz'mina I.M. Dokazatel'naia istoriia kandesartana: proshloe, budushchee i nastoiashchee. Serdechnaia nedostatochnost'. 2015; 16 (5): 303–10. [in Russian]
10. Сиренко Ю.Н., Донченко Н.В. Место кандесартана в современной терапии сердечно-сосудистых заболеваний: обзор доказательств. Артериальная гипертензия. 2011; 4 (18): 114–26. / Sirenko Iu.N., Donchenko N.V. Mesto kandesartana v sovremennoi terapii serdechno-sosudistykh zabolevanii: obzor dokazatel'stv. Arterial'naia gipertenziia. 2011; 4 (18): 114–26. [in Russian]
11. Леонова М.В. Клиническая фармакология антагонистов рецепторов AT II: особенности валсартана. Мед. совет. 2014;17: 66–71. / Leonova M.V. Klinicheskaia farmakologiia antagonistov retseptorov AT II: osobennosti valsartana. Med. sovet. 2014;17: 66–71. [in Russian]
12. Inada Y, Ojima M, Kanagawa R et al. Pharmacologic properties of candesartan cilexetil possible mechanisms of long-term antihypertensive action. J Hum Hypertens 1999; 13 (Suppl. 1): S75–S80.
13. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998; 56: 847–69.
14. Linger T. Differences among angiotensin II type 1 receptor blockers: characterization of candesartan cilexetil. Blood Pressure 2000; 9 (Suppl. 1): 14–8.
15. Vanderheyden PML, Fierens FLP, De Backer JP, Vauquelin G. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type I receptors. Biochem Pharmacol 2000; 59: 927–35.
16. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism. Mol Cel Endocrinol 2009; 302: 237–43.
17. Elmfeldt D, Olofsson В, Meredith P. The relationships between dose and antihypertensive effect of four ATI-receptor Mockers. Differences in potency and efficacy. Blood Press 2002; 11: 293–301.
18. Hasegawa H, Takano H, Kameda Y et al. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
19. Minatoguchi S, Aoyama Т, Kawai N et a. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22 (l): 29–37.
20. Hasegawa H, Takano H, Kameda Y et al. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
21. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
22. Cuspidi C, Muiesan ML, Valagussa L еt al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293–300.
23. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; p. 1195–201.
24. Escobar C, Barrios V, Calderon A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 2008; 10: 208–14.
25. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
26. Kasanuki H, Hagiwara N, Hosoda S et al. HIJ-CREATE Investigators. Angiotensin II receptor blockerbased vs. nonangiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–12.
27. Pfeffer MA, Swedberg K, Granger CB et al. For the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66.
28. McMurray JJV, Östergren J, Swedberg K et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensinconvertingenzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71.
29. Granger CB, McMurray JJV, Yusuf S et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
30. Yusuf S, Pfeffer MA, Swedberg K et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.
31. Кириченко А.А., Романова Е.Е. Влияние блокады ренин-ангиотензин-альдостероновой системы на течение фибрилляции предсердий. Фарматека. 2009; 11 (185): 18–21. / Kirichenko A.A., Romanova E.E. Vliianie blokady renin-angiotenzin-al'dosteronovoi sistemy na techenie fibrilliatsii predserdii. Farmateka. 2009; 11 (185): 18–21. [in Russian]
32. Кириченко А.А., Романова Е.Е. Антигипертензивная терапия у больных пароксизмальной формой фибрилляции предсердий: имеет ли значение выбор препарата? Фарматека. 2009; 11 (185): 69–74. / Kirichenko A.A., Romanova E.E. Antigipertenzivnaia terapiia u bol'nykh paroksizmal'noi formoi fibrilliatsii predserdii: imeet li znachenie vybor preparata? Farmateka. 2009; 11 (185): 69–74. [in Russian]
33. Ducharme A, Swedberg K, Pfeffer MA et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86–92.
34. Евдокимова А.Г., Ложкина М.В., Коваленко Е.В. Особенности применения кандесартана в клинической практике. Consilium Medicum. 2016; 18 (1): 68–73. / Evdokimova A.G., Lozhkina M.V., Kovalenko E.V. Osobennosti primeneniia kandesartana v klinicheskoi praktike. Consilium Medicum. 2016; 18 (1): 68–73. [in Russian]
35. Burgess E, Muirhead N, de Cotret PR et al. SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893–900.
36. Mogensen CE, Neldam S, Tikkanen I et al. For the CALM study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440–4.
37. Norris S, Weinstein J, Peterson K, Thakurta S. Drug Class Review. Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers. Drug Effectiveness Review Project. Oregon Health & Science University 2009.
38. Avila-Funes JA, Amieva H, Barberger-Gateau P et al. Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. J Am Geriatr Soc 2009; 57: 453–61.
________________________________________________
1. Andrushchishina T.B., Morozova T.E. Antagonisty retseptorov angiotenzina II pri lechenii kardiovaskuliarnykh zabolevanii. Consilium Medicum. 2009; 11 (5): 96–101. [in Russian]
2. Jonston CI. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. Am J Hypertens 1992; 10: S13–S26.
3. Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Rekomendatsii po diagnostike i lecheniiu arterial'noi gipertenzii. Kardiologicheskii vestn. 2015; 1: 3. [in Russian]
4. Linger Т. Differences among angiotensin II type 1 receptor blockers: characterization of 19. candesartan cilexetil. Blood Pressure 2000; 9 (1): 14–8.
5. Evdokimova A.G., Lozhkina M.V., Kovalenko E.V., Evdokimov V.V. Klinicheskaia effektivnost' irbesartana u patsientov s serdechno-sosudistymi zabolevaniiami. Serdtse. 2012; 11 (6): 364–8. [in Russian]
6. Jonston CI. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. Am J Hypertens 1992; 10: S13–S26.
7. Giliarevskii S.R. Sovremennye vozmozhnosti blokady renin-angiotenzinovoi sistemy: ostaiutsia li ingibitory angiotenzinprevrashchaiushchego fermenta preparatami pervogo riada? Consilium Medicum. 2010; 12 (5): 18–23. [in Russian]
8. Ostroumova O.D., Khor'kov S.A., Kopchenov I.I. Vozmozhnosti antagonistov retseptorov k angiotenzinu II v organoprotektsii u bol'nykh s arterial'noi gipertoniei: znachenie dlia klinicheskoi praktiki. Consilium Medicum. 2009; 11. [in Russian]
9. Giliarevskii S.R., Golshmid M.V., Kuz'mina I.M. Dokazatel'naia istoriia kandesartana: proshloe, budushchee i nastoiashchee. Serdechnaia nedostatochnost'. 2015; 16 (5): 303–10. [in Russian]
10. Sirenko Iu.N., Donchenko N.V. Mesto kandesartana v sovremennoi terapii serdechno-sosudistykh zabolevanii: obzor dokazatel'stv. Arterial'naia gipertenziia. 2011; 4 (18): 114–26. [in Russian]
11. Leonova M.V. Klinicheskaia farmakologiia antagonistov retseptorov AT II: osobennosti valsartana. Med. sovet. 2014;17: 66–71. [in Russian]
12. Inada Y, Ojima M, Kanagawa R et al. Pharmacologic properties of candesartan cilexetil possible mechanisms of long-term antihypertensive action. J Hum Hypertens 1999; 13 (Suppl. 1): S75–S80.
13. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998; 56: 847–69.
14. Linger T. Differences among angiotensin II type 1 receptor blockers: characterization of candesartan cilexetil. Blood Pressure 2000; 9 (Suppl. 1): 14–8.
15. Vanderheyden PML, Fierens FLP, De Backer JP, Vauquelin G. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type I receptors. Biochem Pharmacol 2000; 59: 927–35.
16. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism. Mol Cel Endocrinol 2009; 302: 237–43.
17. Elmfeldt D, Olofsson В, Meredith P. The relationships between dose and antihypertensive effect of four ATI-receptor Mockers. Differences in potency and efficacy. Blood Press 2002; 11: 293–301.
18. Hasegawa H, Takano H, Kameda Y et al. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
19. Minatoguchi S, Aoyama Т, Kawai N et a. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22 (l): 29–37.
20. Hasegawa H, Takano H, Kameda Y et al. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
21. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
22. Cuspidi C, Muiesan ML, Valagussa L еt al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293–300.
23. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; p. 1195–201.
24. Escobar C, Barrios V, Calderon A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 2008; 10: 208–14.
25. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
26. Kasanuki H, Hagiwara N, Hosoda S et al. HIJ-CREATE Investigators. Angiotensin II receptor blockerbased vs. nonangiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–12.
27. Pfeffer MA, Swedberg K, Granger CB et al. For the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66.
28. McMurray JJV, Östergren J, Swedberg K et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensinconvertingenzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71.
29. Granger CB, McMurray JJV, Yusuf S et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
30. Yusuf S, Pfeffer MA, Swedberg K et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.
31. Kirichenko A.A., Romanova E.E. Vliianie blokady renin-angiotenzin-al'dosteronovoi sistemy na techenie fibrilliatsii predserdii. Farmateka. 2009; 11 (185): 18–21. [in Russian]
32. Kirichenko A.A., Romanova E.E. Antigipertenzivnaia terapiia u bol'nykh paroksizmal'noi formoi fibrilliatsii predserdii: imeet li znachenie vybor preparata? Farmateka. 2009; 11 (185): 69–74. [in Russian]
33. Ducharme A, Swedberg K, Pfeffer MA et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86–92.
34. Evdokimova A.G., Lozhkina M.V., Kovalenko E.V. Osobennosti primeneniia kandesartana v klinicheskoi praktike. Consilium Medicum. 2016; 18 (1): 68–73. [in Russian]
35. Burgess E, Muirhead N, de Cotret PR et al. SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893–900.
36. Mogensen CE, Neldam S, Tikkanen I et al. For the CALM study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440–4.
37. Norris S, Weinstein J, Peterson K, Thakurta S. Drug Class Review. Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers. Drug Effectiveness Review Project. Oregon Health & Science University 2009.
38. Avila-Funes JA, Amieva H, Barberger-Gateau P et al. Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. J Am Geriatr Soc 2009; 57: 453–61.
Авторы
А.А.Кириченко
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1 andrey.apollonovich@yandex.ru
________________________________________________
A.A.Kirichenko
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1 andrey.apollonovich@yandex.ru